An interventional study of Transcatheter aortic valve replacement and Surgical aortic valve replacement in Aortic Valve Stenosis, Cardiovascular Diseases and Heart Diseases, sponsored by Ole De Backer. Active, not recruiting at 9 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-09.
Sponsored by Ole De Backer · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Aortic Valve Stenosis with a site in Finland — 6 open to participants now, 15 under way, none of them phase 3. Aortic Valve Stenosis · Finland.
Among the 27 studies in Aortic Valve Stenosis with a site in Finland, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2016, is one of 8 with no phase, reaches primary completion later than 5 of the 14 other live ones, and was the 9th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →6 of the 27 studies in Aortic Valve Stenosis with a site in Finland are open now. Recruiting first, the newest first:
Ole De Backer · Sites in Finland, Belgium, Denmark and 3 more countries
Ages 18+
Queen Silvia Children's Hospital, Gothenburg, Sweden · Sites in Finland, United States, Austria and 5 more countries
Ages 23 wk–31 wk
Hospital District of Helsinki and Uusimaa · Sites in Finland
Ages 18–80
Universitaire Ziekenhuizen KU Leuven · Sites in Finland, Belgium, Denmark and 5 more countries
Ages 18+
Kuopio University Hospital · Sites in Finland
Ages 30–90
A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 376 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 443 across the 10 interventional studies, 638 across the 17 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 27 have an industry lead sponsor. The 10 most frequent:
Ole De Backer is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Ole De Backer has 3 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Aortic Valve Stenosis with a site in Finland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03444259University of TurkuProspective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Aortic Valve Stenosis with a site in Finland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized clinical trial investigating transcatheter (TAVR) versus surgical (SAVR) aortic valve replacement in patients 75 years of age or younger suffering from severe aortic valve stenosis.
Study hypothesis: The clinical outcome (death of any cause, stroke and rehospitalization (related to the procedure, valve or heart failure)) obtained within one year after TAVR is non-inferior to SAVR.
BACKGROUND: Acquired aortic valve stenosis (AS) is the most common heart valve disease in the Western World with a prevalence of 2-7% at the age of >65 years. If untreated, it may lead to heart failure and death. Surgical aortic valve replacement (SAVR) until recent years has been the definitive treatment for patients with severe symptomatic AS. A less invasive transcatheter aortic valve replacement (TAVR) has been developed and has been a treatment of choice mostly for elderly high risk or inoperable patients. As TAVR technology is continuously evolving and improving, it may be anticipated that it will become a valuable alternative - and even the preferred choice of treatment - for younger, low-risk patients with severe aortic valve stenosis in the near future. However, to date, there is no clinical evidence that supports this hypothesis.
AIM: The purpose of the study is to compare TAVR and SAVR with regard to the intra- and post-procedural morbidity and mortality rate, hospitalization length, functional capacity, quality of life, and valvular prosthesis function in younger, low risk patients with severe bicuspid or tricuspid AS, scheduled for aortic valve replacement.
POPULATION: Younger low risk patients with severe aortic valve stenosis, which are scheduled for aortic valve replacement using a bioprosthesis. Subjects fulfilling the inclusion criteria, not having any exclusion criteria, and consenting to the trial will be randomized 1:1 to TAVR or SAVR with 186 patients in each group.
DESIGN: The study is a randomized clinical multicenter trial. Central randomization with variable block size and stratification by gender and coronary comorbidity will be used. An independent event committee blinded to treatment allocation will adjudicate safety endpoints.
INTERVENTIONS:
TAVR: Any CE-Mark approved transcatheter aortic bioprosthesis may be used in the study, and the choice is at the discretion of the local TAVR team. The transfemoral TAVR procedure may be performed under general anaesthesia, local anaesthesia/conscious sedation, or local anesthesia. Percutaneous coronary intervention (PCI) can be performed up to 30 days prior to TAVR or as a hybrid procedure.
SAVR: The surgical SAVR technique follows standard protocol of the local department of cardio-thoracic surgery. The operation is performed under general anesthesia, which follows standard protocol of the department of anesthesiology. A commercial available surgical aortic bioprosthesis at the surgeons discretion will be implanted. Concomitant coronary artery bypass graft (CABG) surgery may be performed.
END POINTS: The primary endpoint is the composite rate of death of any cause, stroke and rehospitalization (related to the procedure, valve or heart failure) within one year after the procedure. Secondary endpoints are listed below. Follow-up will be performed after 1 and 12 months and yearly thereafter for a minimum of 10 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transcatheter aortic valve replacement
Device: Transcatheter aortic valve replacement
Surgical aortic valve replacement
Device: Surgical aortic valve replacement
Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
Also known as: Transcatheter aortic valve implantation, TAVR, TAVI
Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
Also known as: SAVR
Composite rate of all-cause mortality, stroke and rehospitalization (related to the procedure, the valve or heart failure) within one year after the procedure.
VARC-3 definitions
Time frame: at one year post-procedural.
Procedure time
hours
Time frame: Intraoperative
Duration of index hospitalization
days
Time frame: Number of days from admission to discharge (expected an averge of 7 days)
Composite rate of all-cause mortality, stroke and rehospitalization (related to the procedure, the valve or heart failure)
VARC-3 definitions
Time frame: at 1 month and yearly thereafter up to 10 years post-procedure
Composite rate of all-cause mortality, disabling stroke and rehospitalization (related to the procedure, the valve or heart failure)
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Rehospitalization both composite and individual of related to the procedure, the valve or heart failure)
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Composite rate of all-cause mortality and disabling stroke
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
All-cause mortality
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Cardiovascular mortality
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Non-cardiovascular mortality
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Stroke
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Disabling Stroke
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Non-disabling stroke
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Transient Ischemic attack
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Myocardial Infarction
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Endocarditis
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Valve Thrombosis
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Need for aortic valve re-intervention
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Bleeding (life-threatening or major)
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Vascular complication (major)
VARC-3 defintions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Acute kidney injury (stage 2 or 3)
VARC-3 defintions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Echocardiographic aortic bioprosthesis performance (degree of paravalvular leakage, valve area, mean gradient, prosthesis patient mismatch)
VARC-3 definitions
Time frame: at discharge, 1 and 12 months, and yearly thereafter up to 10 years post-procedure
NYHA functional class
NYHA functional class
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Need for permanent pacemaker
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
New onset atrial fibrillation captured on ECG
VARC-3 definitions
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Left ventricle remodeling as assesed by echocardiography
Left ventricle internal diameter in diastoli
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Quality of life change from baseline
Kansas City Cardiomyopathy Questionnaire, scale 0 (worse) to 100 (better)
Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2016 to primary completion in Feb 2024, 92 months.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 92 months is above that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.